Zobrazeno 1 - 10
of 21 429
pro vyhledávání: ''
Autor:
Lajos Pusztai, Gabriel N. Hortobagyi, Bryan T. Hennessy, Massimo Cristofanilli, Chafika Mazouni, Fabrice Andre, Attila Tordai, W. Fraser Symmans, Cornelia Liedtke, Marjorie C. Green, Ana M. Gonzalez-Angulo, Kenneth R. Hess, Jaime A. Mejia
Publikováno v:
Journal of Clinical Oncology. 41:1809-1815
PURPOSE Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherap
Autor:
Charles L, Vogel, Melody A, Cobleigh, Debu, Tripathy, John C, Gutheil, Lyndsay N, Harris, Louis, Fehrenbacher, Dennis J, Slamon, Maureen, Murphy, William F, Novotny, Michael, Burchmore, Steven, Shak, Stanford J, Stewart, Michael, Press
Publikováno v:
Journal of Clinical Oncology. 41:1638-1645
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ran
Autor:
Virginia Paton, Gracie Lieberman, Melody A. Cobleigh, Debasish Tripathy, Nicholas J. Robert, Charles L. Vogel, Louis Fehrenbacher, Janet M. Wolter, Steven Shak, Susy Scholl, Dennis J. Slamon
Publikováno v:
Journal of Clinical Oncology. 41:1501-1510
PURPOSE Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evalu
Publikováno v:
Journal of Clinical Oncology. 41:1331-1338
PURPOSE Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose
Autor:
Judith E. Carroll, Zev M. Nakamura, Brent J. Small, Xingtao Zhou, Harvey J. Cohen, Tim A. Ahles, Jaeil Ahn, Traci N. Bethea, Martine Extermann, Deena Graham, Claudine Isaacs, Heather S.L. Jim, Paul B. Jacobsen, Brenna C. McDonald, Sunita K. Patel, Kelly Rentscher, James Root, Andrew J. Saykin, Danielle B. Tometich, Kathleen Van Dyk, Wanting Zhai, Elizabeth C. Breen, Jeanne S. Mandelblatt
Publikováno v:
Journal of Clinical Oncology. 41:295-306
PURPOSE To examine longitudinal relationships between levels of C-reactive protein (CRP) and cognition in older breast cancer survivors and noncancer controls. METHODS English-speaking women age ≥ 60 years, newly diagnosed with primary breast cance
Autor:
Thi-Van-Trinh Tran, Carole Rubino, Rodrigue Allodji, Milena Andruccioli, Stéphane Bardet, Ibrahima Diallo, Massimo Dottorini, Jérome Garsi, Per Hall, Michel Henry-Amar, Stephanie Lamart, Françoise Le Thai, Stefan Lönn, Marcel Ricard, Claire Schvartz, Martin Schlumberger, Neige Journy, Florent de Vathaire
Publikováno v:
British Journal of Cancer. 127:2118-2124
Female thyroid cancer survivors are more likely to have a higher risk of breast cancer compared to the general population, and the underlying causes are yet to be understood. The potential role of I-131 treatment on this association remains controver
Publikováno v:
Breast Cancer Research and Treatment. 196:441-451
Neoadjuvant systemic therapy (NAST) can be an effective treatment option for patients with HER2 + or triple negative breast cancer (TNBC). However, its use in geriatric patients is largely understudied. Our aim is to investigate the effect of NAST in
Publikováno v:
Breast Cancer Research and Treatment. 196:67-74
Purpose Elderly patients have different physical condition and tumor biology of breast cancer. Surgical choices for older patients are complicated and several studies have reported that breast conserving surgery (BCS) had better survival than mastect
Autor:
Nirav S, Kapadia, Gabriel A, Brooks, Mary Beth, Landrum, Lauren, Riedel, Pang-Hsiang, Liu, Andrea, Hassol, Amanda S, Tripp, Shalini, Jhatakia, Colleen M, Kummet, Nancy L, Keating
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:39-46
Radiation utilization for breast cancer and metastatic bone disease varies in modality, fractionation, and cost, despite evidence demonstrating equal effectiveness and consensus recommendations such as Choosing Wisely that advocate for higher value c
Autor:
Adriana Garduño-Alanis, Lizbeth Morales-González, Angélica Ángeles-Llerenas, José Zaim Delgado-Ramírez, Carolina Ortega-Olvera, Gabriela Torres-Mejía
Publikováno v:
Cancer Causes & Control. 33:1355-1361
The delay in the time (in calendar days) from the delivery of mammography results to histopathological breast cancer (BC) diagnosis could be associated with more advanced clinical stages, a worse prognosis and higher mortality. Therefore, we assessed